These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 18502982

  • 21. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    Liu P, Xu B, Li J, Lu H.
    FEBS Lett; 2009 Jan 22; 583(2):401-6. PubMed ID: 19111544
    [Abstract] [Full Text] [Related]

  • 22. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C.
    J Cell Biochem; 2008 Jan 01; 103(1):270-83. PubMed ID: 17516511
    [Abstract] [Full Text] [Related]

  • 23. Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
    Yeom SY, Lee SJ, Kim WS, Park C.
    Leuk Res; 2012 Sep 01; 36(9):1172-8. PubMed ID: 22658652
    [Abstract] [Full Text] [Related]

  • 24. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
    Minderman H, Zhou Y, O'Loughlin KL, Baer MR.
    Cancer Chemother Pharmacol; 2007 Jul 01; 60(2):245-55. PubMed ID: 17096161
    [Abstract] [Full Text] [Related]

  • 25. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.
    Cancer Res; 2007 Mar 15; 67(6):2783-90. PubMed ID: 17363600
    [Abstract] [Full Text] [Related]

  • 26. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
    Zheng B, Zhou R, Gong Y, Yang X, Shan Q.
    Int J Lab Hematol; 2012 Jun 15; 34(3):237-47. PubMed ID: 22145750
    [Abstract] [Full Text] [Related]

  • 27. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 28. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
    Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M.
    J Natl Cancer Inst; 2006 Aug 16; 98(16):1142-57. PubMed ID: 16912267
    [Abstract] [Full Text] [Related]

  • 29. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N.
    Anticancer Drugs; 2007 Jul 16; 18(6):677-86. PubMed ID: 17762396
    [Abstract] [Full Text] [Related]

  • 30. PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
    Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L, Mattii L, Battolla B, Capodanno A, Collecchi P, Veroni F, Simi P, Piaggi S, Casini A, Petrini M.
    Leuk Res; 2008 Jan 16; 32(1):103-12. PubMed ID: 17629554
    [Abstract] [Full Text] [Related]

  • 31. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL.
    Leukemia; 2009 Aug 16; 23(8):1507-14. PubMed ID: 19282831
    [Abstract] [Full Text] [Related]

  • 32. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
    Ottosson-Wadlund A, Ceder R, Preta G, Pokrovskaja K, Grafström RC, Heyman M, Söderhäll S, Grandér D, Hedenfalk I, Robertson JD, Fadeel B.
    Mol Pharmacol; 2013 Jan 16; 83(1):245-55. PubMed ID: 23093495
    [Abstract] [Full Text] [Related]

  • 33. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M.
    Leukemia; 2004 Aug 16; 18(8):1357-63. PubMed ID: 15190257
    [Abstract] [Full Text] [Related]

  • 34. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS.
    Cancer Res; 2008 May 01; 68(9):3379-88. PubMed ID: 18451165
    [Abstract] [Full Text] [Related]

  • 35. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X, Qiu W, Kung J, Zhao X, Peng X, Yegappan M, Yen-Lieberman B, Hsi ED.
    Leuk Res; 2008 Feb 01; 32(2):275-85. PubMed ID: 17659339
    [Abstract] [Full Text] [Related]

  • 36. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D, Kaspers GJ, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, van de Ven PM, Zweegman S, Jansen G, Cloos J.
    J Hematol Oncol; 2014 Jan 13; 7():7. PubMed ID: 24418325
    [Abstract] [Full Text] [Related]

  • 37. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A, Erin N.
    Int J Mol Med; 2008 Dec 13; 22(6):817-23. PubMed ID: 19020781
    [Abstract] [Full Text] [Related]

  • 38. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.
    Cancer Chemother Pharmacol; 2008 Apr 13; 61(4):549-58. PubMed ID: 17522864
    [Abstract] [Full Text] [Related]

  • 39. [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin].
    Chen JF, Jin J.
    Zhonghua Zhong Liu Za Zhi; 2009 Dec 13; 31(12):890-3. PubMed ID: 20193325
    [Abstract] [Full Text] [Related]

  • 40. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
    Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J.
    Int J Oncol; 2006 Feb 13; 28(2):439-46. PubMed ID: 16391799
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.